By Josh White
Date: Tuesday 26 Aug 2025
(Sharecast News) - ValiRx announced a new wholly owned subsidiary Blue Ribbon Bio on Tuesday, to consolidate its prostate cancer assets and accelerate development of its Val201 peptide therapy.
By Josh White
Date: Friday 20 Jun 2025
(Sharecast News) - ValiRx confirmed on Friday that Ambrose Healthcare has exercised its option to license the VAL401 oncology asset, in a deal worth up to £16m plus royalties.
By Josh White
Date: Thursday 03 Apr 2025
(Sharecast News) - ValiRx announced the immediate termination of its letter of intent with TheoremRx on Thursday, ending exclusive negotiations originally set to run until 31 May.
Currency | UK Pounds |
Share Price | 0.53p |
Change Today | 0.000p |
% Change | 0.00 % |
52 Week High | 2.15p |
52 Week Low | 0.42p |
Volume | 1,670,723 |
Shares Issued | 374.35m |
Market Cap | £1.97m |
RiskGrade | 435 |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income | ![]() |
---|
Growth |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
No dividends found |
Time | Volume / Share Price |
14:34 | 183,426 @ 0.54p |
13:24 | 483 @ 0.50p |
12:38 | 100,000 @ 0.53p |
12:09 | 7 @ 0.50p |
11:57 | 1 @ 0.50p |
You are here: research